

BioStock Life Science Summit 2019

biotech | pharma | diagnostics | devices



Connecting Innovation & Capital.

BioStock Life Science Summit

biotech | pharma | diagnostics | devices

BIO Connecting Innovation & Capital.

October 25 | 2018 | Medicon Village | Lund | Sweden





It's a tradition!

We proudly welcome you to the 2nd annual BioStock Life Science Summit. Hosted at Medicon Village in Lund where innovation and capital connect, we aim to make The Summit the Nordic region's premier meeting place for entrepreneurs and investors, always offering an exciting sneak peek into the future of biotech, pharma, diagnostics and health care devices.

We hope you will enjoy these two days!

Sincerely, the BioStock Team

**Host & moderator**

Jonas Söderström, CEO BioStock

25k

Newsletter
Subscribers

55k

Monthly Web
Visitors (av.)

250k

Total Investor
Network Reach

82%

SWE C-level
Subscribers



About BioStock

BioStock is the Nordic region's leading digital news and analytics service focusing exclusively on the life science sector. By webcasting the BioStock Life Science Summit 2019 live via our multi-channel media platform and media partner network, the presentations, panel discussions and industry insights will be reaching a broad base of professional and retail investors in Sweden as well as internationally.

BioStock's daily news briefings are closely monitored by a majority of life science investors and industry executives in the Nordic region. To subscribe and learn more about BioStock, feel free to explore our free content at biostock.se.

Disclaimer

The information in this folder has been collected from a variety of public sources which BioStock considers to be reliable, and reasonable efforts have been made to verify the information whenever feasible, but BioStock cannot and does not warrant that the information is accurate or complete. The information herein may be partly based on forward-looking statements which involve several risks and uncertainties, many of which are external and thus beyond the individual company's control. The folder shall be considered as containing general information, and is not intended as investment advice, individual or otherwise. All investments in financial instruments are connected to risks. BioStock does not provide investment advice. Biostock shall not take responsibility for any direct or indirect damages that may be caused due to any decisions made in connection with the information in this folder. This folder is not directed to legal or natural persons in jurisdictions where the provision of the folder would be in breach of mandatory applicable law. By choosing to read this folder, you understand and accept this disclaimer.

Day 1 – Wednesday Oct 23

Venue Medicon Village, Scheelevägen 2, 223 63 Lund
Building 302 (Inspira)
Main Auditorium

| Time | Event & Participant | Time | Event & Participant |
|--------------------|--|--------------|--|
| 09.00–09.30 | Arrival & Registration, coffee and light breakfast | 13.20 | <i>Panel session 2: Investing in Innovations – From discovery to market</i> |
| 09.30 | Welcome note: BioStock, Jonas Söderström | | Mattias Häggblom, Swedbank Robur Medica |
| 09.35 | Immunovia, Julie Silber | | Daniel Bolanowski, Arctic Aurora LifeScience |
| 09.45 | Spago Nanomedical, Mats Hansen | | Claus Johansen, Danske Bank Asset Management |
| 09.55 | Aptahem, Mikael Lindstam | | |
| 10.05 | Networking Break | 13.45 | Acarix, Per Persson |
| | | 13.55 | Clinical Laserthermia Systems, Lars-Erik Eriksson |
| 10.20 | <i>Panel session 1: Investor Insights – In search of the next Nordic unicorn</i> | 14.05 | Lipum, Einar Pontén |
| | Björn Odlander, HealthCap | 14.15 | Dicot, Göran Beijer |
| | Ingrid Teigland Akay, Hadean Ventures | 14.25 | BioStock, Jonas Söderström |
| | Johan Kördel, Lundbeckfonden Ventures | 14.30 | Networking Break |
| | Carl Borrebaeck, Lund University | 14.45 | WntResearch, Peter Morsing |
| 10.45 | Cereno Scientific, Björn Dahlöf | 14.55 | Idogen, Anders Karlsson |
| 10.55 | Endovab, Stefan Sowa | 15.05 | Iconovo, Orest Lastow |
| 11.05 | BrainCool, Martin Waleij | 15.15 | CanImGuide, Carl-Magnus Högerkorp |
| 11.15 | Follicum, Jan Alenfall | 15.25 | Networking Break |
| 11.25 | Networking Break | 15.40 | <i>Panel session 3: (Re)fueling the unique Nordic ecosystem – Corporate finance & capital raise insights</i> |
| 11.40 | LIDDS, Monica Wallter | | Conny Granelli, ABG Sundal Collier |
| 11.50 | Xintela, Evy Lundgren-Åkerlund | | Fredrik Rahl, Sedermera Fondkommission |
| 12.00 | Omnio, Patric Stafshede | | Stefan Lundberg, Erik Penser Bank |
| 12.10 | Immunicum, Carlos de Sousa | | Kristofer Krolak, Vator Securities |
| 12.20 | Lunch | | Jonas Ljungström, Naventus |
| | | 16.05 | NeuroVive Pharmaceutical, Erik Kinnman |
| | | 16.15 | Xbrane Biopharma, Martin Åmark |
| | | 16.25 | MedicPen, Fredrik Westman |
| | | 16.35 | Innovosens, Sirisha Adimatyam |
| | | 16.45 | Saniona, Jørgen Drejer |
| | | 16.55 | Closing notes Jonas Söderström, BioStock |
| | | 17.00 | Drinks & Networking |

Day 2 – Thursday Oct 24: Session 1 *(By invitation only)***Session 2** *(Open to public)*

Venue Medicon Village, Scheelevägen 2, 223 63 Lund
The Spark
Room: "Sharience" ground floor

Venue **Note! Change of venue (3 min walk)**
Medicon Village, Scheelevägen 2, 223 63 Lund
Building 302 (Inspira)
Main Auditorium

Time **Event & Participant****Time** **Event & Participant****08.30–09.30** **Arrival & Registration, coffee and light breakfast**

09.00 Welcome note: Jonas Söderström, BioStock

09.05 RhoVac, Anders Månsson

09.15 Cereno Scientific, Björn Dahlöf

09.25 Omnio, Patric Stafshede

09.35 Acarix, Per Persson

09.45 Iconovo, Orest Lastow

09.55 **Networking Break**

10.10 Lipum, Einar Pontén

10.20 WntResearch, Peter Morsing

10.30 Idogen, Anders Karlsson

10.40 Immunicum, Carlos de Sousa

10.50 Immunovia, Julie Silber

11.00 **Networking Break**

11.15 Xbrane, Martin Åmark

11.25 MedicPen, Fredrik Westman

11.35 Dicot, Göran Beijer

11.45 BrainCool, Martin Waleij

11.55 Endovab, Stefan Sowa

12.05 **Lunch**

13.05 CanimGuide, Carl-Magnus Högerkorp

13.15 *TBD*

13.25 Xintela, Evy Lundgren-Åkerlund

13.35 Innovosens, Sirisha Adimatyam

13.45 Saniona, Jørgen Drejer

13.55 **Networking Break**

14.15 Introduction: Jonas Söderström, BioStock

14.20 **Panel session: Industry insights – Partnering in the Nordic region**

Åsa Sjöholm-Timén, AstraZeneca

Ralf W. Ackermann, Bayer

Anna Gran, Johnson & Johnson

14.40 Partnering presentation:

Åsa Sjöholm-Timén & Kay Brickmann

AstraZeneca

14.55 Partnering presentation:

Ralf W. Ackermann, Bayer

15.10 Partnering presentation:

Anna Gran, Johnson & Johnson

15.25 **Networking Break****Live Interview sessions: Key learnings from entering a Big Pharma partnership**

Jan Børge Jakobsen, Bayer

Per Nilsson, Pilloxa

Kay Brickmann, AstraZeneca

Martin Olovsson, OnDosis

16.00 Closing notes: Jonas Söderström, BioStock

16.30 **Drinks & Networking**

Investors & Financial Experts



HealthCap

HealthCap is a European venture capital firm investing exclusively in life sciences, founded in 1996 with offices in Stockholm and Lausanne.

Represented by: Dr Björn Odlander, Managing Partner and Founder



Hadean Ventures

Hadean Ventures is a European life science fund manager with offices in Oslo and Stockholm. Hadean Ventures invests in life science companies across Europe with focus on the Nordic region.

Represented by: Ingrid Teigland Akay, Managing Partner and Founder



Lundbeckfonden Ventures

Lundbeckfonden, established in 1954, is one of the largest commercial foundations in Denmark, worth over 60 billion Dkk. Yearly, the foundation grants over 500 MDkk to Danish-based, biomedical sciences research – primarily in the field of brain disorders.

Represented by: Johan Kördel, Senior Partner Lundbeckfonden Ventures

Professor Carl Borrebaeck

Professor Carl Borrebaeck received the first chair as professor of Immunotechnology in Scandinavia when the Department was inaugurated in 1989. Since then, he has been awarded several prizes and recognitions for his contributions to cancer research and entrepreneurship in the biotech sector.



Arctic Aurora LifeScience

Arctic Aurora LifeScience is an equity fund investing in global biotechnology and pharmaceutical companies. Arctic Aurora is part of Arctic Fund Management AS, an independent Nordic Investment Manager, based in Oslo.

Represented by: Daniel Bolanowski, Life Science Analyst



Danske Bank Asset Management

Danske Bank Asset Management manages over 200 billion EUR in assets and is one of the leading asset managers in the Nordic region.

Represented by: Claus Johansen, Senior Portfolio Manager



Swedbank Robur Medica

Swedbank Robur Medica is an actively managed equity fund, investing in global healthcare companies mainly in the US, Europe and Japan. Swedbank Robur Medica has 9 billion SEK in assets under management.

Represented by: Mattias Häggblom, Portfolio Manager



ABG Sundal Collier

ABG Sundal Collier is a Nordic investment bank founded in Oslo in 2001, covering corporate finance services and equity sales and research.

Represented by: NN, TT



ERIK PENSER BANK

Erik Penser Bank

Erik Penser Bank is a Swedish privately owned bank who offers services within wealth management and corporate finance. Erik Penser Bank was founded in 1994 and is based in Stockholm.

Represented by: Stefan Lundberg, Senior Corporate Finance Manager



Naventus

Naventus is a Swedish investment bank who offers services within strategic advisory, equity capital markets, debt capital markets and mergers and acquisitions. Naventus is based in Stockholm.

Represented by: Jonas Ljungström, Senior Partner



Sedermera Fondkommission

Sedermera Fondkommission is a Swedish corporate finance firm and Certified Adviser founded in 2003. Sedermera was founded in 2003.

Represented by: Fredrik Rahl, Director of Sales & Capital Markets



Vator Securities

Vator Securities is a Swedish corporate finance firm headquartered in Stockholm, covering corporate finance services, capital markets and strategic advisory and equity research.

Represented by: Kristofer Krolak, Partner

Homepage Immunovia.com

Ticker & Market IMMNOV, Nasdaq Stockholm

Shares issued 20M (updated 16 Oct 2019)

Market Cap 2 936 MSEK (updated 16 Oct 2019)

CEO Mats Grahn

Chairman Carl Borrebaeck



| Major stakeholders | Capital % | Votes % |
|---------------------------|------------------|----------------|
| Carl Borrebaeck | 8.8 | 8.8 |
| Ålandsbanken | 8.4 | 8.4 |
| Svenska Handelsbanken | 5.1 | 5.1 |
| Per Mats Ohlin | 4.6 | 4.6 |
| Sara Andersson Ek | 4.6 | 4.6 |

As of June 30, 2019

About Immunovia

Immunovia aims to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia's core technology platform, IMMray, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray PanCan-d that could be the first blood-based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. Immunovia also run a project in non-small cell lung cancer (NSCLC) in collaboration with a major pharma company, with very promising initial results.

Immunovia is presented by Julie Silber, Director of Investor Relations

Homepage spagonanomedical.se

Ticker & Market SPAG, Spotlight Stock Market

Shares issued 21M (updated 16 Oct 2019)

Market Cap 231 MSEK (updated 16 Oct 2019)

CEO Mats Hansen

Chairman Eugen Steiner



| Major stakeholders | Capital % | Votes % |
|---------------------------|------------------|----------------|
| Peter Lindell | 18.2 | 18.2 |
| HealthInvest Partners | 7.8 | 7.8 |
| Avanza Pension | 7.7 | 7.7 |
| Eva Redhe | 7.1 | 7.1 |
| Mikael Lönn | 6.3 | 6.3 |

As of September 30, 2019

About Spago Nanomedical

Swedish Spago Nanomedical is based in Lund and focuses on nanomedicine. The company develops nanomaterials for tumour diagnostics and the treatment of cancer, with its nanoparticles designed to accumulate specifically in tumors utilising the enhanced permeability and retention (EPR) effect. Its two development projects SpagoPix and Tumorad are both built on proprietary nanomaterials. SpagoPix is a nanomedical contrast agent for magnetic resonance tomography (MRI) whilst Tumorad enables internal radiation therapy of tumours, so-called radionuclide therapy. SpagoPix (SN132D) is currently undergoing a phase I study in patients with confirmed breast cancer with the primary aim of evaluating safety. The developmental project Tumorad holds patents on the two largest markets, the USA and Europe.

Spago Nanomedical is presented by Mats Hansen, CEO

APTACHEM

Homepage aptahem.com

Ticker & Market APTA, Spotlight Stock Market

Shares issued 43M (updated 15 Oct 2019)

Market Cap 133 MSEK (updated 15 Oct 2019)

CEO Mikael Lindstam

Chairman Kjell G Stenberg

| Major stakeholders | Capital % | Votes % |
|----------------------------|------------------|----------------|
| Ivar Nordqvist | 27.5 | 27.5 |
| Nordnet Pensionsförsäkring | 12.0 | 12.0 |
| Avanza Pension | 6.3 | 6.3 |
| AB Svedala Finans | 2.4 | 2.4 |
| Gunvald Berger | 1.3 | 1.3 |

As of July 16, 2019

About Aptahem

Aptahem is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company's primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in sepsis patients, among others. The company possesses patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.

Aptahem is presented by Mikael Lindstam, CEO

Homepage cerenoscientific.se

Ticker & Market CRNO B, Spotlight Stock Market

Shares issued 40M (updated 15 Oct 2019)

Market Cap 165 MSEK (updated 15 Oct 2019)

CEO Sten R Sörensen

Chairman Catharina Bäärnhielm



| Major stakeholders | Capital % | Votes % |
|---------------------------|------------------|----------------|
| Niklas Bergh | 5.6 | 11.8 |
| GU Ventures | 4.8 | 3.7 |
| Avanza Pension | 4.2 | 3.2 |
| Kjetil Myrliid Aasen | 3.5 | 2.7 |
| Sverker Jern | 3.0 | 7.1 |

As of August 26, 2019

About Cereno Scientific

Cereno Scientific is developing novel preventive medicine to treat thrombosis-related disease, based on the body's own intelligent clot-busting system. Cardiovascular disease is currently the leading cause of death worldwide. Current therapies are connected to an increased risk of bleeding and, as a result, low effectiveness due to lower dosing levels. In turn, this leads to a high risk of new blood clots. Cereno Scientific's drug candidate, CS1, is expected to provide a possibility for an effective prevention of thrombosis and a lower risk for serious bleeding complications than with current blood thinning therapies. CS1 is an innovative controlled release formulation of a known compound, and as such is expected to have a relatively short development time. Cereno Scientific also develops CS014, a preclinical phase compound.

Cereno Scientific is presented by Björn Dahlöf, CMO

Homepage endovab.com

Ticker & Market – (Private Company)

Shares issued –

Market Cap –

CEO Stefan Sowa

Chairman Krister Liungman



About Endovab

Privately-owned Endovab is a Swedish company based in Uppsala focusing on the development of devices aimed at facilitating endovascular surgery. This is an increasingly popular technique for minimally invasive surgery via the blood vessels and the company has developed the Liungman Guidewire Fixator. The device has been CE-marked and is the first ever guidewire that can be distally fixated in an artery, allowing for a secure guidewire position which enables the surgeon to perform several procedures in parallel. The company is currently looking to establish commercial use and develop the second generation of their instrument.

Endovab is presented by Stefan Sowa, CEO

Homepage braincool.se

Ticker & Market BRAIN, Spotlight Stock Market

Shares issued 40M

Market Cap 230 MSEK

CEO Martin Waleij

Chairman Jens Kinnander



| Major stakeholders | Capital % | Votes % |
|----------------------------|------------------|----------------|
| Nordnet Pensionsförsäkring | 14.3 | 14.3 |
| Avanza Pension | 13.7 | 13.7 |
| Cormac Invest | 2.1 | 2.1 |
| Swedbank Försäkringar | 1.6 | 1.6 |
| Håkan Samuelsson | 0.9 | 0.9 |

As of September 5, 2019

About BrainCool

BrainCool is a Swedish medical device company located at Medicon Village, Lund. The company develops patented medical cooling technologies focusing on two business areas: Brain Cooling and Pain Management. The medical cooling technology, (therapeutic hypothermia), lowers patients' body temperature to help reduce the risk of injury to the brain following a period of insufficient blood flow due to an ischemic event. The company develops cooling systems for treatment of stroke-, cardiac arrest- and migraine patients, as well as products for the prevention of oral mucositis and neuropathy, major severe side effects of cancer treatment. The estimated annual market value of these treatment areas is significant, and the company is currently focusing on penetrating the American and German markets.

BrainCool is presented by Martin Waleij, CEO

Homepage follicum.se

Ticker & Market FOLLI, Spotlight Stock Market

Shares issued 68M (updated 15 Oct 2019)

Market Cap 189 MSEK (updated 15 Oct 2019)

CEO Jan Alenfall

Chairman Gun-Britt Fransson



| Major stakeholders | Capital % | Votes % |
|----------------------------|------------------|----------------|
| Avanza Pension | 9.8 | 9.8 |
| Brushamn Invest AB | 5.2 | 5.2 |
| Mats Lundberg | 3.2 | 3.2 |
| Nordnet Pensionsförsäkring | 3.2 | 3.2 |
| Kudu AB | 2.7 | 2.7 |

As of September 18, 2019

About Follicum

Follicum is a biotech company focused on the discovery and development of peptide-based drugs. The primary focus is in hair growth stimulation, where Follicum has obtained very promising results with FOL-005 in a recently completed clinical trial. In diabetes, Follicums research has resulted in a new peptide class which significantly increases the release of insulin in pre-clinical models. The company was founded in 2011, and is based in Lund, Sweden.

Follicum is presented by Jan Alenfall, CEO

Homepage liddspharma.com

Ticker & Market LIDDS, Nasdaq First North

Shares issued 23M

Market Cap 414 MSEK

CEO Monica Wallter

Chairman Jan Törnell



| Major stakeholders | Capital % | Votes % |
|---------------------------|------------------|----------------|
| Wikow Venture | 8.9 | 8.9 |
| Daniel Lifveredson | 8.2 | 8.2 |
| Nyenburgh Holding BV | 5.2 | 5.2 |
| Bengt Sporre | 3.9 | 3.9 |
| Recipharm Venture Fund | 3.0 | 3.0 |

As of September 30, 2019

About LIDDS

LIDDS, a Swedish company based in Uppsala, develops injectable drugs for cancer and other diseases based on their proprietary NanoZolid technology. NanoZolid helps solve some of the main problems with the way drugs work in the body and which affect patient quality of life. The technology enables the controlled, long-term and personalised release of drugs for up to six months and can be combined with traditional small molecules as well as with larger molecules. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects in clinical and preclinical phase for cytostatics and immunoactive agents. In September the company could announce positive preliminary results from a phase IIb study in prostate cancer proving the NanoZolid technology's suitability for local cancer treatment.

LIDDS is presented by Monica Wallter, CEO

Homepage xintela.se

Ticker & Market XINT, Nasdaq First North Stockholm

Shares issued 39M (updated 15 Oct 2019)

Market Cap 172 MSEK (updated 15 Oct 2019)

CEO Evy Lundgren-Åkerlund

Chairman Gregory Batcheller



| Major stakeholders | Capital % | Votes % |
|---------------------------|------------------|----------------|
| Bauerfeind AG | 25.5 | 25.5 |
| Evy Lundgren-Åkerlund | 10.5 | 10.5 |
| Avanza Pension | 5.1 | 5.1 |
| Fredrik Olsson | 5.0 | 5.0 |
| Pär Åke Oldentoft | 4.1 | 4.1 |

As of July 5, 2019

About Xintela

Xintela develops medical products within regenerative medicine and oncology based on its proprietary marker technology, XINMARK, that is used to isolate and quality assure stem cells for the treatment of the joint disease osteoarthritis. Studies on horses have shown that the stem cells are safe and that they have a therapeutic effect on the articular cartilage and the underlying bone after an injury. Xintela has established its own GMP-facility to produce stem cells for clinical studies. In the oncology program, XINMARK is used for the development of an ADC treatment with initial focus on the aggressive brain tumor glioblastoma with positive preclinical results. Since mid 2018, German Bauerfeind AG is a major stakeholder following a directed new share issue of 50 MSEK.

Xintela is presented by Evy Lundgren-Åkerlund, CEO

Homepage omnio.se

Ticker & Market – (Private Company)

Shares issued –

Market Cap –

CEO Patric Stafshede

Chairman Lars Johansson



About Omnio

Omnio is a privately-owned biotechnical research and development company located in Umeå, northern Sweden founded in 2001 by Professor Tor Ny. The company's focus is to develop biological drug candidates based on the plasma-derived protease plasminogen. Omnio performs pre-clinical research on plasminogen and the plasminogen activator system to find solutions to several diseases such as chronic wounds, periodontitis, and tympanic membrane perforation. Fundamental for the development is pre-clinical research studies conducted in collaboration with Umeå University.

Omnio is presented by Patric Stafshede, CEO

Homepage immunicum.se

Ticker & Market IMMU, Nasdaq Stockholm

Shares issued 92M (updated 16 Oct 2019)

Market Cap 842 MSEK (updated 16 Oct 2019)

CEO Carlos de Sousa

Chairman Michael Oredsson



| Major stakeholders | Capital % | Votes % |
|--------------------------------------|------------------|----------------|
| Fourth Swedish National Pension Fund | 7.6 | 7.6 |
| Avanza Pension | 7.5 | 7.5 |
| Nordnet Pensionsförsäkring | 6.2 | 6.2 |
| Gladiator | 3.9 | 3.9 |
| Loggen Invest AB | 3.5 | 3.5 |

As of September 30, 2019

About Immunicum

Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. The company's goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. According to the company, its lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications.

Immunicum is presented by Carlos de Sousa, CEO

Homepage acarix.com

Ticker & Market ACARIX, Nasdaq First North

Shares issued 23M (updated 16 Oct 2019)

Market Cap 132 MSEK (updated 16 Oct 2019)

CEO Per Persson

Chairman Werner Braun



| Major stakeholders | Capital % | Votes % |
|---------------------------|------------------|----------------|
| SEED Capital DK II K/S | 20.6 | 20.6 |
| Sunstone LSV Fund II K/S | 20.6 | 20.6 |
| Puhua Jingxin | 11.5 | 11.5 |
| Coloplast | 7.3 | 7.3 |

As of July 31, 2019

About Acarix

Acarix is a Swedish medtech company that was established in 2009 as a spin-off from Coloplast, a research and development collaboration based on pioneering research from the Aalborg University in Denmark. The company markets CADScor System, a non-invasive and ultra-sensitive analytical device designed to support a safe, reliable and cost-effective rule-out of significant coronary artery disease (CAD) at the very first stage of the diagnostic pathway. Since 2010, the Danish investors SEED Capital and Sunstone Life Science Ventures has supported Acarix towards its market introduction. After receiving the CE-mark, Acarix was listed on Nasdaq First North Premier in 2016. The first market introduction took place in Germany in 2017. Today, the CADScor System is also available in Scandinavia and Austria.

Acarix is presented by Per Persson, CEO

Homepage clinicallaser.se

Ticker & Market CLS B, Nasdaq First North

Shares issued 34M (updated 16 Oct 2019)

Market Cap 405 MSEK (updated 16 Oct 2019)

CEO Lars-Erik Eriksson

Chairman Hans von Celsing



| Major stakeholders | Capital % | Votes % |
|----------------------------|------------------|----------------|
| Avanza Pension | 9.1 | 7.9 |
| Nordnet Pensionsförsäkring | 8.1 | 7.0 |
| Kg Tranberg Medical | 4.2 | 8.1 |
| Elano Aktiebolag | 2.7 | 6.9 |
| Six Sis AG | 1.0 | 3.1 |

As of December 31, 2018

About CLS

Clinical Laserthermia Systems, founded in 2006, is a Swedish med tech company based in Lund. The company works towards the further development and increased efficiency of treatment of solid cancer tumours. CLS has developed The TRANBERG |Thermal Therapy System which is used for image guided high precision soft tissue thermal therapy and ablation procedures. CLS products are approved and marketed in the US and in Europe. Targeted user groups include medical specialists in surgical oncology and oncologic interventional radiology. The first TRANBERG| Mobile Laser Units has been bought by a US hospital and the first patients, with early stage prostate tumor disease, have been treated using CLS single-use products. In Europe CLS has ongoing clinical studies in France, Italy, UK, Germany, Portugal and Sweden for several indications.

CLS is presented by Lars-Erik Eriksson, CEO

Homepage lipum.se

Ticker & Market – (Private Company)

Shares issued –

Market Cap –

CEO Einar Pontén

Chairman Ulf Björklund



About Lipum

Privately-owned Lipum aims to improve the quality of life for the millions of children and adults suffering from chronic inflammatory diseases, as well as decrease the considerable health care and societal costs associated with these diseases. Lipum has identified a unique target for treatment of chronic inflammatory diseases - a protein denoted bile salt-stimulated lipase (BSSL). Lipum has collected original research data proving the efficacy of the compound in several established arthritis models and are currently developing a humanised monoclonal antibody that target BSSL. Lipum's proposed treatment and developed drug candidate can qualify for an orphan drug designation. The company is actively seeking partners to further its drug development and has previously received soft funding from Novo Seeds, Innovationsbron and Umeå Biotech Incubator.

Lipum is presented by Einar Pontén, CEO

Homepage dicot.se

Ticker & Market DICOT, Spotlight Stock Market

Shares issued 16M (updated 16 Oct 2019)

Market Cap 61 MSEK (updated 16 Oct 2019)

CEO Lars Jonsson

Chairman Lars Jonsson



| Major stakeholders | Capital % | Votes % |
|-----------------------------|------------------|----------------|
| Jarl Wikberg | 50.8 | 50.8 |
| Avanza Pension | 8.3 | 8.3 |
| Uppsala Universitet Holding | 4.1 | 4.1 |
| Bertil Lindkvist | 3.4 | 3.4 |
| Bengt Walfridson | 3.0 | 3.0 |

As of July 17, 2019

About Dicot

Dicot is a pharmaceutical company focused on drug discovery and the development of novel lifestyle drugs to enrich patients' lives. The company develops and manufactures medicines for the treatment of erectile dysfunction and premature ejaculation. The company's lead product, Libiguin, for the treatment of sexual dysfunctions, is in pre-clinical development. The company recently raised 20.3 MSEK through an oversubscribed rights issue and 2 MSEK through a fully subscribed overallotment issue.

Dicot is presented by Göran Beijer, CEO

Homepage wntresearch.com

Ticker & Market WNT, Spotlight Stock Market

Shares issued 25M (updated 15 Oct 2019)

Market Cap 210 MSEK (updated 15 Oct 2019)

CEO Peter Morsing

Chairman Gudrun Anstrén



| Major stakeholders | Capital % | Votes % |
|----------------------------|------------------|----------------|
| Avanza Pension | 12.8 | 12.84 |
| Nordnet Pensionsförsäkring | 10.3 | 10.31 |
| Kjell G Stenberg | 6.0 | 6.0 |
| Tommy Andersson | 4.2 | 4.2 |
| Lars-Erik Forsgårdh | 2.1 | 2.1 |

As of July 17, 2019

About WntResearch

WntResearch develops a new type of cancer drug that works by inhibiting the ability of tumor cells to spread throughout the body and form metastases. Metastases are the main reason why people die from cancer, yet there are no effective treatments aimed to prevent metastasizing. Experimental preclinical models have shown that Foxy-5 – the company's most advanced drug candidate – has the ability to reduce the movement and invasion capacity of tumor cells and thus counteract the onset of metastases. Results from phase I in patients with colon, prostate or breast cancer show a favorable safety profile and pharmacokinetics and provided early indications of biological activity. The company recently initiated a phase II multicenter study in colon cancer with the objective to evaluate the anti-metastatic effect of Foxy-5.

WntResearch is presented by Peter Morsing, CEO

Homepage idogen.com

Ticker & Market IDOGEN, Spotlight Stock Market

Shares issued 48M (updated 16 Oct 2019)

Market Cap 48 MSEK (updated 16 Oct 2019)

CEO Anders Karlsson

Chairman Agneta Edberg



| Major stakeholders | Capital % | Votes % |
|---------------------------|------------------|----------------|
| Avanza Pension | 7.1 | 7.1 |
| John Fällström | 4.9 | 4.9 |
| Kronolund AB | 2.1 | 2.1 |
| Andreas Johansson | 1.9 | 1.9 |
| Leif G Salford | 1.6 | 1.6 |

As of September 30, 2019

About Idogen

Idogen is a Swedish biotechnology company that develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs or the body's own cells or tissue. The term "tolerogenic" refers to the immune system's selective tolerance of a specific pathogenic or immune activating antigen following treatment with Idogen's therapy. Idogen's intention is to revolutionize the treatment of several disorders in which the body's immune system does not function as it should, and for which there is a major unmet medical need – such as in autoimmune diseases, organ transplant rejection and in patients who have developed anti-drug antibodies.

Idogen is presented by Anders Karlsson, CEO

Homepage iconovo.se

Ticker & Market ICO, Nasdaq First North

Shares issued 7M (updated 16 Oct 2019)

Market Cap 371 MSEK (updated 16 Oct 2019)

CEO Orest Lastow

Chairman Mats Johansson



| Major stakeholders | Capital % | Votes % |
|-------------------------------------|------------------|----------------|
| Mats Johansson | 13.6 | 13.6 |
| Lastow Consulting AB (Orest Lastow) | 12.5 | 12.5 |
| Alto Invest | 10.8 | 10.8 |
| SEB Life International | 8.8 | 8.8 |
| Johan Lundgren | 6.8 | 6.8 |

As of September 30, 2019

About Iconovo

Iconovo was founded in 2013 by individuals with extensive experience in inhalation development. The company develops inhalers with associated drug preparation that are mainly used to treat asthma and COPD, but Iconovo also has the expertise to develop products for new types of inhaled drugs such as vaccines. Iconovo currently have three ready-to-use inhalers with various attributes to suit different dosing regimens. By partnering with Iconovo, pharmaceutical companies and generic companies can access a complete pharmaceutical product, thus avoiding the complicated and costly early stages of the development phase. Iconovo licenses its patented products to its customers and offers a faster route to the lower risk inhalation market and at a lower cost.

Iconovo is presented by Orest Lastow, CEO

Homepage canimguide.com
Ticker & Market – (Private Company)
Shares issued –
Market Cap –
CEO Carl-Magnus Högerkorp
Chairman Nils Siegbahn



About CanImGuide

CanImGuide was founded in 2006 in order to further develop new treatment for primarily cancer, based on research carried out by a team led by Professor Leif Håkansson at the University of Linköping, Sweden. After discovering and demonstrating that a previously unknown immunosuppressive peptide, P3028, is formed in malignant tumours, the company developed the proprietary drug P28R, a peptide with two modes of action. In tumours the drug effectively unblocks the blocking effect of P3028. CanImGuide plans to take P28R to proof of concept in cancer patients and will then partner their immune-oncology program with a pharma partner with a presence in this particular area.

CanImGuide is presented by Carl-Magnus Högerkorp, CEO

Homepage neurovive.com

Ticker & Market NVP, Nasdaq Stockholm

Shares issued 185M (updated 16 Oct 2019)

Market Cap 273 MSEK (updated 16 Oct 2019)

CEO Erik Kinnman

Chairman David Laskey-Pooley



| Major stakeholders | Capital % | Votes % |
|----------------------------|------------------|----------------|
| Försäkringsaktiebolaget | 12.4 | 12.4 |
| Danske Bank International | 4.6 | 4.6 |
| John Fällström | 2.7 | 2.7 |
| Euroclear Bank | 2.5 | 2.5 |
| Nordnet Pensionsförsäkring | 2.5 | 2.5 |

As of June 30, 2019

NeuroVive Pharmaceutical

NeuroVive Pharmaceutical focuses on the development of treatments for mitochondrial diseases, a group of rare diseases significant market potential. The company is a leader within the field of mitochondrial medicine, with one project in clinical phase I (KL1333) for chronic treatment of primary mitochondrial diseases and one project, in preparation for clinical trials (NV354), for treatment of primary mitochondrial diseases with Complex I deficiency. KL1333 has been granted orphan drug status in both the USA and the EU. NeuroVive's ambition is to take drugs for rare diseases through clinical development and all the way to market. The company has also a project for traumatic brain injury, NeuroSTAT, in clinical phase and are looking for partners for this project. The R&D portfolio also consists of projects for NASH and cancer.

NeuroVive Pharmaceutical is presented by Erik Kinnman, CEO

Homepage xbrane.com

Ticker & Market XBRANE, Nasdaq Stockholm

Shares issued 15M (updated 16 Oct 2019)

Market Cap 462 MSEK (updated 16 Oct 2019)

CEO Martin Åmark

Chairman Anders Tullgren



| Major stakeholders | Capital % | Votes % |
|---------------------------|------------------|----------------|
| Serendipity Ixora | 14.6 | 14.6 |
| STADA Arzneimittel AG | 8.2 | 8.2 |
| Avanza Pension | 7.0 | 7.0 |
| Swedbank Robur Fonder | 5.9 | 5.9 |
| Paolo Sarmientos | 4.8 | 4.8 |

As of July 31, 2019

About Xbrane Biopharma

Xbrane is a commercial phase Swedish biopharmaceutical company that develops, manufactures and produces biosimilars. Xbrane has a patented protein production platform for development of biosimilars and world leading expertise in biosimilars. Xbrane's headquarter is located in Solna and the company's in-house research and development facilities are located in Sweden and Italy.

Xbrane Biopharma is presented by Martin Åmark, CEO

Homepage medicpen.com

Ticker & Market MPEN, Spotlight Stock Market

Shares issued 157M (updated 16 Oct 2019)

Market Cap 94 MSEK (updated 16 Oct 2019)

CEO Fredrik Westman

Chairman Sigrun Axelsson



| Major stakeholders | Capital % | Votes % |
|---------------------------|------------------|----------------|
| Avanza Pension | 11.2 | 11.2 |
| Asko Tapio Paavola | 1.8 | 1.8 |
| Mushe Samuelsson | 1.6 | 1.6 |
| Peter Lantz | 1.3 | 1.3 |
| Stefan Lindstrand | 1.3 | 1.3 |

As of July 16, 2019

About MedicPen

MedicPen, with its base in Lomma, Sweden develops digital solutions that enables healthcare organisations to simplify administration of medicine and enable staff to focus on other important tasks. These solutions will also make life easier and safer for patients who take several medications to be in charge of their own medication. To achieve this MedicPen has developed the dispenser MedimiSmart in which up to 28 pills can be stored in separate compartments. MedimiSmart also reminds the user through light and sound features when it is time to take the medication. The product is CE-marked and fulfills the requirements to be sold as a medtech class I product in the EU. MedicPen is currently undertaking a rights issue of circa 30 MSEK.

MedicPen is presented by Fredrik Westman, CEO

Homepage innovosens.com

Ticker & Market - (Private Company)

Shares issued -

Market Cap -

CEO Sirisha Adimatyam

Chairman -



About Innovosens

Innovosens is a privately-owned Swedish company, based in Malmö, and focusing on developing treatment for diabetes. Diabetes is a growing global health issue and Innovosens aims to develop strategies for early screening, diagnosis and management of diabetic complications. The company does this using the technology Innovosens APP that provides easy access of glucose and other parameters to both users and caregivers on continuous basis and as well as reference to the historical values for in-depth analysis on the trends of each measured analytes.

Innovosense is presented by Sirisha Adimatyam, CEO

Homepage saniona.com

Ticker & Market SANION, Nasdaq Stockholm Small Cap

Shares issued 28M (updated 16 Oct 2019)

Market Cap 697 MSEK (updated 16 Oct 2019)

CEO Jørgen Drejer

Chairman J. Donald deBethizy



| Major stakeholders | Capital % | Votes % |
|----------------------------|------------------|----------------|
| BNY MELLON | 9.4 | 10.9 |
| Avanza Pension | 6.1 | 5.5 |
| Thomas Feldthus | 4.3 | 5.1 |
| Leif Andersson Consulting | 3.4 | 4.1 |
| Nordnet Pensionsförsäkring | 3.1 | 3.1 |

As of September 30, 2019

About Saniona AB

Saniona is a research and development company based outside Copenhagen, focused on drugs for diseases of the central nervous system and eating disorders. The biotech company currently has five programs in clinical development. Saniona intends to develop and commercialise treatments for orphan indications such as Prader-Willi syndrome and hypothalamic obesity on its own. The Prader-Willi project has recently reported positive results in a phase II study. The company's research is focused on ion channels and the company has a broad portfolio of research programs as well as partnerships with Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V and Cadent Therapeutics.

Saniona is presented by Jørgen Drejer, CEO

Homepage rhovac.com

Ticker & Market RHOVAC, Spotlight Stock Market

Shares issued 19M (updated 16 Oct 2019)

Market Cap 304 MSEK (updated 16 Oct 2019)

CEO Anders Månsson

Chairman Mikael Ørum



| Major stakeholders | Capital % | Votes % |
|-------------------------------|------------------|----------------|
| RQ Solutions ApS | 14.1 | 14.1 |
| Ventac Holding Ltd (Cyprus) | 12.5 | 12.5 |
| Nordic Cross Asset Management | 6.4 | 6.4 |
| Avanza Pension | 6.2 | 6.2 |
| Nordnet Pensionsförsäkring | 3.6 | 3.6 |

As of September 18, 2019

About RhoVac

RhoVac AB conducts research and development of immunotherapeutic drugs. The company's main focus is the development of a therapeutic cancer vaccine with the potential to prevent or limit metastasis in cancer. RhoVac's first drug candidate – RV001 – has successfully completed clinical phase I/II and clinical phase IIb development has been initiated, with the first patients treated during the fall. The research has been conducted since 2007 primarily at the University Hospital in Herlev, Denmark, by a world-class research team within its niche.

RhoVac is presented by Anders Månsson, CEO

Homepage astrazeneca.com

Ticker AZN

Market LSE, Nasdaq OMX, NYSE

Market Cap 115 BUSD (updated 16 Oct 2019)

CEO Pascal Soriot

Chairman Leif Johansson



Key figures 2018

Total sales 22 100 MUSD

Earnings per share 1.70 USD

R&D expenses 5 932 MUSD

Number of employees 61 000 people

About AstraZeneca

AstraZeneca is a global science-led biopharmaceutical company that engages in the discovery, development, commercialization of prescription medicines. The company focuses on research and development three main therapy areas: Oncology, Cardiovascular, Renal & Metabolism and Respiratory. The company was founded in 1999 through the merger of Astra of Sweden and Zeneca of the United Kingdom. AstraZeneca is headquartered in Cambridge, UK, with strategic research facilities in Cambridge, UK, Gaithersburg, USA and Gothenburg, Sweden.

AstraZeneca is presented by Åsa Sjöholm-Timén, Associate Transaction Director, and Kay Brickman, Business Development Director

Homepage bayer.com

Ticker BAYN

Market Xetra

Market Cap 62 BUSD (updated 16 Oct 2019)

CEO Werner Baumann

Chairman Werner Wenning



Key figures 2018

Total sales 38 600 MUSD

Earnings per share 9.27 USD

R&D expenses 5 783 MUSD

Number of employees 117 000 people

About Bayer

The Bayer Group is divided into main three divisions, Pharmaceuticals, Consumer health and Crop Science. Animal Health is also a reporting unit within the group. The pharmaceutical division is researching, developing and marketing specialty-focused innovative medicines primarily in the therapeutic areas of cardiology, oncology, gynecology, hematology and ophthalmology. Bayer has principal research centers in Berlin, Wuppertal and Cologne in Germany, in San Francisco and Berkeley in the US, and also in Turku, Finland and in Oslo, Norway.

Bayer is presented by Ralf W. Ackermann, Regional Medical Director

Homepage jnj.com

Ticker JNJ

Market NYSE

Market Cap 350 BUSD (updated 16 Oct 2019)

CEO Alex Gorsky

Chairman Alex Gorsky



Key figures 2018

Total sales 81 600 MUSD

Earnings per share 5.61 USD

R&D expenses 10 775 MUSD

Number of employees 135 000 people

About Johnson & Johnson

Johnson & Johnson is the largest and the most broadly-based healthcare company in the world, with more than 130 000 employees globally. The company has three key segments, Consumer, Pharmaceutical and Medical Devices. Johnson & Johnson Innovation is a part of the company that focuses on accelerating all stages of innovation worldwide and forming collaborations with entrepreneurs and Johnson & Johnson's global healthcare businesses.

Johnson & Johnson is presented by Anna Gran, New Venture Lead Nordics

Homepage pilloxa.com

Ticker & Market – (Private Company)

Shares issued –

Market Cap –

CEO Fransesco Mazzotta

Chairman Per Nilsson



About Pilloxa

Pilloxa has developed a smart pillbox in order to facilitate medication adherence. By combining hardware, software and cloud services, they aim to address a problem widely observed by patients, pharmacists and caregivers. The company was founded in 2015 by a joint venture program run by the Royal Institute of Technology, Karolinska Institutet and Stockholm County Council.

Pilloxa is represented by Per Nilsson, Co-founder

Homepage ondosis.com

Ticker & Market – (Private Company)

Shares issued –

Market Cap –

CEO Martin Olovsson

Chairman Staffan Ternström



About OnDosis

OnDosis is developing products for individualized dosing in diseases with a significant burden on patients and healthcare such as ADHD, pain management and immunosuppression for organ transplants. The company was founded by GU Ventures and Martin Olovsson in 2017 and is based in Gothenburg.

OnDosis is represented by Martin Olovsson, CEO



TACK TILL VÅRA PARTNERS:

NYHETSBYRÅN DIREKT | MEDICON VILLAGE | ENDPOINTS NEWS

Subscribe to our newsletter to learn about future events

[BIOSTOCK.SE](https://biostock.se)